Bio-Rad Laboratories's Total Liabilities for the quarter that ended in Mar. 2026 was €2,542 Mil.
Bio-Rad Laboratories's quarterly Total Liabilities
increased
from Sep. 2025 (€2,521.58 Mil) to Dec. 2025 (€2,666.96 Mil) but then
declined
from Dec. 2025 (€2,666.96 Mil) to Mar. 2026 (€2,541.98 Mil).
Bio-Rad Laboratories's annual Total Liabilities
declined
from Dec. 2023 (€3,262.59 Mil) to Dec. 2024 (€2,669.03 Mil) and
declined
from Dec. 2024 (€2,669.03 Mil) to Dec. 2025 (€2,666.96 Mil).
Bio-Rad Laboratories Total Liabilities Related Terms
Bio-Rad Laboratories Total Liabilities Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Bio-Rad Laboratories's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a Total Liabilities of €2,542 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Total Liabilities too high?
Bio-Rad Laboratories' current Total Liabilities is €2,542 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Total Liabilities compare to GKOS and BRKR?
Bio-Rad Laboratories' Total Liabilities of €2,542 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Total Liabilities is €2,542 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €275.94, compared to a current price of €257.60 — trading 6.6% below its estimated fair value. The current Total Liabilities is €2,542 Mil. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Total Liabilities is €2,542 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of €257.60 is trading 6.6% below its estimated GF Value™ of €275.94.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
Total Liabilities: €2,542 Mil
GF Value™: €275.94 vs. price of €257.60 (6.6% below fair value)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for FRA:BUWA
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
